ANTX Stock Overview
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
AN2 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.48 |
| 52 Week High | US$22.22 |
| 52 Week Low | US$2.43 |
| Beta | -0.24 |
| 1 Month Change | -15.93% |
| 3 Month Change | -87.51% |
| 1 Year Change | -70.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.90% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Shareholder Returns
| ANTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -18.4% | -2.2% | -3.7% |
| 1Y | -70.3% | 11.6% | 20.5% |
Return vs Industry: ANTX underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: ANTX underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ANTX volatility | |
|---|---|
| ANTX Average Weekly Movement | 23.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANTX's share price has been volatile over the past 3 months.
Volatility Over Time: ANTX's weekly volatility has increased from 17% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 41 | Eric Easom | www.an2therapeutics.com |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc. Fundamentals Summary
| ANTX fundamental statistics | |
|---|---|
| Market cap | US$73.53m |
| Earnings (TTM) | -US$64.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs ANTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.73m |
| Earnings | -US$64.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANTX perform over the long term?
See historical performance and comparison